LOVEDA WINKLES: Open Payments
NPI 1730899279 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,227 in 78 payments from 16 companies in 2025. Trend: 2023 $3,125 · 2024 $3,962 · 2025 $2,227
Food & beverage: $2,220Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $617 |
| Alkermes, Inc. | 4 | $277 |
| Teva Pharmaceuticals USA, Inc. | 7 | $242 |
| Axsome Therapeutics, Inc. | 4 | $204 |
| Otsuka America Pharmaceutical, Inc. | 13 | $179 |
| Janssen Pharmaceuticals, Inc | 2 | $138 |
| Vanda Pharmaceuticals Inc. | 7 | $137 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 4 | $67 |
Products named: VRAYLAR, LYBALVI, Auvelity, REXULTI, UZEDY, SPRAVATO, FANAPT, COBENFY.
Industry payments across TX — which companies pay providers there.
